SI
INKT icon

Sofinnova Investments’s MiNK Therapeutics INKT Stock Holding History

Sofinnova Investments’s Portfolio INKT Stock Details INKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-33,100
Closed -$745K – 63
2022
Q1 		$745K Sell
33,100
-1,450
-4% -$43.6K 0.06% 56
2021
Q4 		$1.54M Buy
+34,550
New +$4.11M 0.09% 64

Other funds holding INKT

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sofinnova Investments's INKT Position: Q2 2022 in Review

Sofinnova Investments sold out of MiNK Therapeutics (INKT) in Q2 2022, closing a stake of 33,100 shares — an estimated $745K sold.

Sofinnova Investments first reported a position in INKT in Q4 2021 and held it in 2 quarters. The position peaked at $1.54M in Q4 2021. 11 funds tracked by Wall St. Rank hold INKT as of Q2 2022.

  • Sofinnova Investments reported no remaining MiNK Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Sofinnova Investments sold 33,100 MiNK Therapeutics shares in Q2 2022, an estimated $745K.
  • Sofinnova Investments first reported a position in MiNK Therapeutics in Q4 2021 and held it in 2 quarters.
  • Sofinnova Investments's MiNK Therapeutics position peaked at $1.54M in Q4 2021.
  • 11 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q2 2022.

Based on Sofinnova Investments's 13F filing for Q2 2022, filed 15 Aug 2022.